Eli Lilly to Acquire Merida Biosciences in $2.88 Billion Deal
Eli Lilly announced it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, aiming to expand its pipeline of treatments targeting immunity-related and allergic diseases. The acquisition aligns with Lilly's broader strategy of aggressive deal-making fueled by strong demand for its obesity drugs. Merida is developing therapies focused on selectively targeting antibodies involved in immune disorders. Its lead candidate, MER511, is currently in early-stage development for autoimmune conditions like Graves' disease and thyroid eye disease.
Tickers: $LLY
Topics: acquisitions immunology pharmaceuticals